SCHEMBL24913887

SCHEMBL24913887

CN(C)Cc1cc2c(c(N[C@H]3CCOC3)c1)CN(C(=O)OC(C)(C)C)CC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 2/20 0.38
▸ ESR2 Q92731 1/20 0.38
▸ NR1H2 P55055 1/20 0.38
▸ MTOR P42345 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ EPHX1 P07099 1/20 0.34
▸ BRD4 O60885 2/20 0.34
▸ KRAS P01116 1/20 0.34
▸ STS P08842 1/20 0.33
▸ PRMT5 O14744 1/20 0.33
▸ WDR77 Q9BQA1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30156900 1.00 GPR119 (0.38) GPR119ESR2NR1H2MTORALDH1A1
SCHEMBL31013959 0.92 GPR119 (0.38) GPR119ALDH1A1JAK2JAK1NPC1
SCHEMBL29168670 0.87 BRD4 (0.36) MAPK1BRD4PRMT5WDR77
SCHEMBL29168674 0.87 BRD4 (0.36) MAPK1BRD4PRMT5WDR77
SCHEMBL30156775 0.86 ESR2 (0.37) ESR2NR1H2MTORALDH1A1NPC1
SCHEMBL24914090 0.86 ESR2 (0.37) ESR2NR1H2MTORALDH1A1NPC1
SCHEMBL24913918 0.86 GPR119 (0.38) GPR119ESR2NR1H2MTORALDH1A1
SCHEMBL31014038 0.86 GPR119 (0.38) GPR119ESR2NR1H2MTORALDH1A1
SCHEMBL30156745 0.86 GPR119 (0.38) GPR119ESR2NR1H2MTORALDH1A1
SCHEMBL31013883 0.86 ESR2 (0.49) ESR2NR1H2MTORALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651955-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2025-11-26 — — EP disclosed
US-20240293392-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2024-09-05 — — US disclosed
WO-2024153947-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2024-07-25 — — WO disclosed
CN-117693507-A Inhibitor compounds 奈奥芬莱有限公司 2024-03-12 — — CN disclosed
WO-2023002165-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2023-01-26 — — WO disclosed
WO-2023002165-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240293392-A1 INHIBITOR COMPOUNDS MSH2, PMS2, MSH6 GPR119 2087/4885ESR2 568/4885NR1H2 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback